NARA Discovery
Article Details
← Back to Search Results
Journal Article

Mitochondrial genome variation in male LHON patients with the m.11778G > A mutation

Agnieszka Piotrowska-Nowak; Maciej R. Krawczyński; Ewa Kosior-Jarecka; Anna M. Ambroziak; Magdalena Korwin; Monika Ołdak; Katarzyna Tońska; Ewa Bartnik
Metabolic Brain Disease · Vol. 35, Issue 8 · pp. 1317-1327 · 2020

Abstract

Leber hereditary optic neuropathy (LHON) is a mitochondrial disorder with symptoms limited to a single tissue, optic nerve, resulting in vision loss. In the majority of cases it is caused by one of three point mutations in mitochondrial DNA (mtDNA) but their presence is not sufficient for disease development, since ~50% of men and ~10% women who carry them are affected. Thus additional modifying factors must exist. In this study, we use next generation sequencing to investigate the role of whole mtDNA variation in male Polish patients with LHON and m.11778G > A, the most frequent LHON mutation. We present a possible association between mtDNA haplogroup K and variants in its background, a combination of m.3480A > G, m.9055G > A, m.11299 T > C and m.14167C > T, and LHON mutation. These variants may have a negative effect on m.11778G > A increasing its penetrance and the risk of LHON in the Polish population. Surprisingly, we did not observe associations previously reported for m.11778G > A and LHON in European populations, particularly for haplogroup J as a risk factor, implying that mtDNA variation is much more complex. Our results indicate possible contribution of novel combination of mtDNA genetic factors to the LHON phenotype.

Bibliographic Information

JournalMetabolic Brain Disease
PublisherSpringer
Publication Date2020-12-01
Publication Year2020
Volume35
Issue8
Pages1317-1327
Document TypeJournal Article
eISSN1573-7365
DOI10.1007/s11011-020-00605-3

Access Information

NARA Access Coverage1986-01-01~Current
Journal Homepagehttps://www.springer.com/journal/11011
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.